Advertisment Fosfocin
Indian Journal of Critical Care Medicine
An open access publication of ISCCM™ 
 
Users online: 1572 
     Home | Login 
  About Current Issue Archive Search Instructions Online Submission Subscribe Etcetera Contact  
Read this article

 


    Article Cited by others

EDUCATION FORUM

Biological agents targeting beyond TNF-alpha

Sharma Rashmi, Sharma Chaman Lal, Mahajan Annil

Year : 2008| Volume: 12| Issue : 4 | Page no: 181-189

   This article has been cited by
 
1 Distinct Cytokine Profiles in Patients with Oligoarticular Juvenile Idiopathic Arthritis after <i>in</i> <i>Vitro</i> Blockade of Interleukin (IL)-1 and Tumor Necrosis Factor (TNF)-a
Martina Kirchner,Leo Strothmann,Anja Sonnenschein,Wilma Mannhardt-Laakmann
World Journal of Vaccines. 2014; 04(03): 110
[Pubmed]  [Google Scholar] [DOI]
2 Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with vitiligo
Al-Harthi, F. and Zouman, A. and Arfin, M. and Tariq, M. and Al-Asmari, A.
Genetics and Molecular Research. 2013; 12(3): 2196-2204
[Pubmed]  [Google Scholar]
3 Juvenile idiopathic arthritis: Management and therapeutic options
Ruth, N.M. and Passo, M.H.
Therapeutic Advances in Musculoskeletal Disease. 2012; 4(2): 99-110
[Pubmed]  [Google Scholar]
4 Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Gasparyan, A.Y. and Ayvazyan, L. and Cocco, G. and Kitas, G.D.
Current Pharmaceutical Design. 2012; 18(11): 1543-1555
[Pubmed]  [Google Scholar]
5 Tumor necrosis factor and Alzheimers disease: A cause and consequence relationship
Sharma, V. and Thakur, V. and Bhandari, S. and Singh, S.N. and Guleria, R.
Klinik Psikofarmakoloji Bulteni. 2012; 22(1): 86-97
[Pubmed]  [Google Scholar]
6 Current and emerging drugs for the treatment of inflammatory bowel disease
Triantafillidis, J.K. and Merikas, E. and Georgopoulos, F.
Drug Design, Development and Therapy. 2011; 5: 185-210
[Pubmed]  [Google Scholar]
7 Biologics in childrens autoimmune disorders: Efficacy and safety
Breda, L. and Del Torto, M. and De Sanctis, S. and Chiarelli, F.
European Journal of Pediatrics. 2011; 170(2): 157-167
[Pubmed]  [Google Scholar]
8 Biologics in childrens autoimmune disorders: efficacy and safety
Luciana Breda,Marianna Torto,Sara Sanctis,Francesco Chiarelli
European Journal of Pediatrics. 2011; 170(2): 157
[Pubmed]  [Google Scholar] [DOI]
9 Have we overestimated the benefit of human(ized) antibodies?
Daniel R. Getts,Meghann T. Getts,Derrick P. McCarthy,Emily ML Chastain,Stephen D. Miller
mAbs. 2010; 2(6): 682
[Pubmed]  [Google Scholar] [DOI]
10 Have we overestimated the benefit of human(ized) antibodies?
Getts, D.R. and Getts, M.T. and McCarthy, D.P. and Chastain, E.M.L. and Miller, S.D.
mAbs. 2010; 2(6): 682-694
[Pubmed]  [Google Scholar]
11 Advances in biologic agents for the treatment of rheumatoid arthritis
Gur, A. and Oktayoglu, P.
Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry. 2010; 9(1): 24-34
[Pubmed]  [Google Scholar]

 

Online since 7th April '04
Published by Wolters Kluwer - Medknow